Awesome Stock Sponsert EAPH

EAPH - Our New Awesome Sub Penny Pick & Pharmaceutical-Play

EAPH is our New Awesome Pick this week and it looks to be the Hottest Undervalued Sub Penny Pharma-Play in the Micro-Cap markets.

EAPH flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal, FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB.

Members whats so great about EAPH is that its market cap is dirt cheap and still UNDER $1MM. Yes you read that right, we have found the Next Mega hidden Wallstreet gem, EAPH, with Mega upside potential having a product that could be considered the Next V-I-A-G-R-A for Women.
EAPH proprietary gel formulation is an innovative and unique transdermal delivery system. EAPH flagship product, VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
EAPH is an undiscovered wallstreet gem that's on the verge of a mega breakout with both exciting breaking news and upside potential. EAPH could be the Next most talked about Micro-Cap play having a super small float (only 63 MM) and Outstanding share count (only 128MM) as of May 2013 via www.otcmarkets.com/stock/EAPH/company-info.


EAPH - Record Breaking News just Released Tonight

Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer

TORONTO--(BUSINESS WIRE)--Easton Pharmaceuticals (EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Mr. Neil Mellor will join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of experience in the pharmaceutical industry, both in Canada and Europe. The majority of Mr. Mellor’s background is in sales, marketing and business development for companies such as Merck, Pharmacia (now Pfizer), and Solvay Pharma (now Abbott Laboratories).

Over the past 10 years, Mr. Mellor has been Associate Director of Business Development at Solvay Pharma. In addition, Mr. Mellor served as President of the Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and remains an active member of the Board of the CHLA. Mr. Mellor is currently the President of Global Health Link, a healthcare consulting company serving Canadian and US clients. We are especially pleased to have such an accomplished professional as Mr. Mellor on board to help with our future plans for our products, beginning with our lead product VIORRA TM,” commented Mr. John Adams, of Easton Pharmaceuticals’. "Mr. Mellor’s vast experience in marketing and licensing will help us navigate the sometimes uncertain waters of the different markets Easton Pharmaceuticals is considering, and will help us focus on the design and execution of key business activities which will enrich our pending commercialization efforts.”

About Easton Pharmaceuticals Inc (EAPH):

Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of US$10 BB.

The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal , FSAD (Female-Sexual-Arousal-Disorder). The world market for products which treat this disorder is in excess of US$2 BB. VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.

For more information, visit www.eastonpharma.com or www.ashleybiomedical.com

Contact:

Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: info@lamindustries.com
Email and Media Relations: info@ashleybiomedical.com

Contact:
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
+1-416-619-0291
+1-347-284-0192
orMedia Relations:
info@lamindustries.com
or
info@ashleybiomedical.com

With just a quick glance at a chart of Easton Pharmaceuticals Inc. (OTCMKTS:EAPH), it may appear as if the stock was still spinning wheels, drifting listlessly between $0.005 and $0.012. The longer you look at a chart of EAPH, however, the more you have to wonder if a bullish paradigm shift is underway.

For those not familiar with the company, EAPH is a biopharma name. Its claim to fame is small but well-received library of topical treatments for everything from sexual dysfunction to stretch marks to varicose veins... creams and ointments created when the company was operating under the moniker LAM Industries. Its name was changed in 2010 to Easton Pharmaceuticals, though technically speaking, it doesn't have any actual FDA-approved, internally-administered drugs in its portfolio.... or didn't, anyway. The company is wading back into drug waters, taking the medical marijuana route.

Biotech trading veterans will know how big of a deal that could be for Easton Pharmaceuticals and EAPH shareholders. The advent of legalized marijuana - mostly for medicinal purposes, but also for recreational uses in some states - has put hemp and marijuana stocks at center stage for nearly a year now, and has been very good for those related stocks. EAPH didn't participate in most of that euphoria, as it only announced it was developing a medical marijuana product until early June, and didn't offer any real details of its plans until late August.

The timing and news are academic at this point, however. What matters most now, to us, are the bullish hints the chart is dropping... they're pointing to more upside.

Since early August when Easton Pharmaceuticals put itself back on the map by announcing it was getting into the medical marijuana race, we've seen a string of higher lows; we're also working higher highs (we've already made one higher high). At the same time, the volume the stock's been producing since the news made the company 'real' is noticeable better than the volume we were seeing before the news. Finally, Easton Pharmaceuticals is now finding support at its key long-term moving average lines like the 100-day line (gray) and the 200-day moving average line (green).


It admittedly doesn't seem like much to go on, but often, the subtle clues are the best ones. EAPH is slowly but surely on the mend. In fact, it's already mended - now it's just firming up its foundation from which it can stage an even bigger rally. It may not seem like much right now, but Easton Pharmaceuticals is setting itself up to be one of Q4's better Cinderella stories.

the medical Marijuana industry could reach nearly $9 billion nationwide in five years, as more states in the United States clear the way to likely legalize marijuana for medicinal purposes

EAPH still a newborn at that area but lots of developmets hits since then:
Aug 23, 2013 Easton Pharmaceuticals, Inc. Provides Update on Its Medical Marijuana Initiatives
Aug 20, 2013 OTC Daily Alert Stock Watch - Easton Pharmaceuticals (OTC: EAPH)
Aug 14, 2013 Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial Samples of Its Re-Formulated Viorra and Other Recently Added Portfolio Products
Jul 9, 2013 Andrew Wellington Headlines Ivy Family Office Network New York City Mid Year 2013 Forum
Jun 8, 2013 Easton Pharmaceuticals Announces Three New Additional Products and a Revision to Its Viorra Flagship Product Towards Resuming Its Latin American & South East Asia Initiatives
Jun 6, 2013 Easton Pharmaceuticals, Inc. Announces Its Entrance into the Medical Marijuana Sector
Jun 5, 2013 Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer

Relating Aug 23 pr:,EAPH "has entered into discussions with 2 private independent companies in Canada for a proposed joint venture or partnership where it would share in any revenues generated in the medical Marijuana industry. Both of the companies currently possess growers licenses within various Provinces in Canada with one of them having affiliations within a clinical marijuana friendly state."

NEIL MELLOR(only 3 months here) -THE COO IS a Genius:
investorshub.advfn.com/boards/read_msg.aspx?message_id=91360366

As Mentioned above other MJ companies trading 20-150 times EAPH's CAP.but EAPH has better assets/liabilities ratio,and great SS.(250M A/S,127M O/S).

EAPH trading LESS than 1m cap(.0075 PPS),assets/liabilities >1

that's is why we think EAPH could be a life changer.


EAPH: First Viorra Marketing Advertisement on the Web:

www.pearlwhitemediahosting.com/emerging/

Why is it new:

Just click on the web page at the bottom of my post.
Then you scroll right to the bottom of that page...
On the left side you will see.

Those 2 lines are indicating 2 things

The copyright: Emerging Women's Healthcare. Google it, you will find nothing. So it's brand new...

And the Designer of that web page: Montreal Web Design by Pearlwhitemedia.com

That last line is clickable to bring you to their site.

The copyright of Pearl White Media is dated 2013.
So, again the Viorra Marketing advertisement cannot be very old.

Moreover, the web page address is still: www.pearlwhitemediahosting.com/emerging/,
instead of Emerging Women's Healthcare or whatever...

I really think that Neil Mellor is just starting the marketing campaign about Viorra.
He probably gave the first contract to Pearl White Media Inc..

That web page may still need some SEO,SERP,SEM,SEA,SMO,SMM,SERM... optimizations before being approved by Neil.
Then, that web page will have a different address, probably: Emerging Women's Healthcare, or it may be integrated into the future website: www.ashleybiomedical.com/ , for the part 2 of the advertisement campaign, just before going Viral.  

The company has 60 days to perform its due diligence and review the line of products as well as any intellectual property including any patents or patent pendings that may come with the acquisition. The list of products includes an Anti-Ageing HEMP based Anti-Ageing Moisturizer, a product fortified with HEMP oil which is derived from a different form of Cannabis plant known to have high amounts of proteins and amino acids to compliment the companies medical Marijuana initiatives. As well as encompassing HEMP oil, the HEMP based Anti-Ageing moisturizer uses pure botanical natural ingredients derived from plants, including organic herbs. Other products include a specialized anti-ageing serum fortified with high amounts of Vitamin C, a skin discoloration / age spot treatment gel and an anti-cellulite varicose veins treatment system.

The Product line and the company the products are being acquired from will stay confidential until closing of a final definitive agreement, which the company believes has a high probability of closing. Both companies have 60 days in which to come to terms and close on the final agreement. Whether the transaction closes or not, it is anticipated that Easton will be providing assistance to these products by lending the use of its own technology to help improve the products efficacy and delivery through the skin. Should the deal close, this acquisition will bring Easton into the $426 Billion a year Cosmetics Industry which will coincide and complement its therapeutic line of products including its main product, “VIORRA”, a product to help treat FSAD (Female Sexual Arousal Disorder) utilizing ingredients which the FDA classifies as safe (GRAS).

In other developments, the Company has received its shipment of its main ingredient HA for final trial batch samples of Viorra and its other products, but is still waiting on additional ingredients which are expected shortly. Once complete, the trial samples will be shipped to Mexico and other parts of Latin America where the company anticipates completing and obtaining governmental regulatory approval which would allow the products to be sold in those vast markets. Although its new revised website has experienced delays for various reasons including final design labeling, all of these products as well as its current line of therapeutic products and recently acquired FSAD Drug will be listed and detailed very shortly.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered drugs, therapeutic healthcare products and beauty anti-aging cosmetic products. Its therapeutic healthcare products are focused on conditions that impact a large and expanding number of consumers including health and lifestyle issues related to female and male sexual dysfunction, treatment of certain pain, wound healing, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of $10 billion while the world market for anti-ageing / beauty cosmetics is estimated at over $426 Billion.

The company's updated gel formulation is an innovative and thought to be unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For More Information Visit

www.eastonpharma.com www.ashleybiomedical.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.

Contact:

Carla Pepe, Marketing Director

Easton Pharmaceuticals Inc.

Tel: +1(416) 619-0291

Tel: +1(347) 284-0192

Media and Investor Relations: info@lamindustries.com & info@ashleybiomedical.com


Easton Pharmaceuticals Inc.

Carla Pepe, Marketing Director

Tel: +1(416) 619-0291

Tel: +1(347) 284-0192

or

Media and Investor Relations:

info@lamindustries.com

info@ashleybiomedical.com